Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Focused Risk Assessment

The legacy of general health and science information has long served as a foundational resource for public understanding of medical risks and therapeutic benefits. Within this broad domain, the dissemination of knowledge about pharmaceutical interventions has historically emphasized both efficacy and safety, fostering an informed public discourse. As this heritage evolved, it naturally expanded to encompass more specialized areas of concern, particularly those arising from long-term medication use. One such area involves the relationship between bisphosphonate therapy, commonly prescribed for bone density disorders, and rare but serious adverse events. The transition from general health awareness to a focused occupational exposure concern begins with recognizing that certain patient populations—such as those undergoing prolonged treatment with drugs like Fosamax—may face elevated risks that warrant closer scrutiny. This pivot is not merely clinical but also contextual, as the same mechanisms that inform patient safety in a healthcare setting can be applied to occupational environments where exposure to similar agents or risk factors occurs. By bridging from the general health context to the specific query of Fosamax and osteonecrosis of the jaw, we shift the analytical lens toward how such risks might manifest in workplace settings, where cumulative exposure or procedural factors could amplify vulnerability. This transition maintains a neutral academic tone, avoiding mechanistic claims while setting the stage for a focused examination of occupational exposure pathways.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) involves the death of bone tissue in the jaw, often presenting as exposed bone that fails to heal after dental procedures or spontaneously. According to FDA-approved labeling, ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition may be diagnosed through clinical examination, imaging, and exclusion of other causes. The labeling notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Fosamax Pharmacology and Reported Adverse Effects

Fosamax (alendronate sodium) is a bisphosphonate that inhibits bone resorption by osteoclasts, thereby increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined; for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Adverse reactions reported in clinical trials include gastrointestinal symptoms, with incidences of decreases in serum calcium and phosphate similar between Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The safety profile of once-weekly Fosamax 70 mg was similar to daily 10 mg dosing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The exact mechanism by which bisphosphonates like Fosamax contribute to ONJ is not fully established, but several pathways are proposed. Bisphosphonates suppress bone turnover by inhibiting osteoclast activity, which may impair the jawbone's ability to repair microdamage or respond to infection and trauma. The jawbone's unique characteristics, as highlighted by multiscale characterization, may make it particularly susceptible to these effects (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, the labeling identifies known risk factors for ONJ, including invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

The FDA-approved labeling for Fosamax includes a specific warning under section 5.4 titled 'Osteonecrosis of the Jaw,' which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that ONJ can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling also provides information on the time to onset of symptoms, which varied from one day to several months after starting the drug, and notes that most patients had relief of symptoms after stopping, though a subset had recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Establishing causation between Fosamax and ONJ in individual patients requires careful evaluation. Known risk factors include invasive dental procedures, cancer, concomitant therapies, poor oral hygiene, and co-morbid disorders (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, discontinuation of the drug may lead to symptom relief, but recurrence can occur with rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling recommends discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Timeline Between Exposure and Documented Harm

The timeline for ONJ development after Fosamax exposure is variable. The labeling reports that the time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This suggests that both short-term and long-term use can be associated with ONJ, though the risk appears to accumulate over time. For patients who develop ONJ, most experience relief after stopping the drug, but a subset may have recurrence if rechallenged (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It works by inhibiting bone resorption by osteoclasts, thereby increasing bone mass and reducing fracture risk.

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

Osteonecrosis of the jaw involves the death of bone tissue in the jaw, often presenting as exposed bone that fails to heal after dental procedures or spontaneously. Diagnosis is through clinical examination, imaging, and exclusion of other causes. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate exposure.

How long after starting Fosamax can ONJ develop?

The time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may also increase with longer duration of use.

What should I do if I develop symptoms of ONJ while taking Fosamax?

If you develop symptoms such as exposed bone in the jaw, pain, or delayed healing after dental procedures, consult your healthcare provider. The labeling recommends discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, but recurrence can occur if rechallenged.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.